PDCD1 and nasopharyngeal carcinoma: Therefore, anti-PD-1 therapy combined with anti-CTLA4 or anti-LAG3 treatment may be a potential immunotherapy strategy for EBV DNA Sero+ NPC, which is expected to further improve the response rate in this high-risk population.